Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

228
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
228
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

252
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
252
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

733
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
733

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lack of Antidepressant Effects of Low-Voltage-Sensitive T-Type Calcium Channel Blocker Ethosuximide in a Chronic Social Defeat Stress Model: Comparison with (R)-Ketamine.

The international journal of neuropsychopharmacology·2018
Same author

Role of Inflammatory Bone Markers in the Antidepressant Actions of (R)-Ketamine in a Chronic Social Defeat Stress Model.

The international journal of neuropsychopharmacology·2018
Same author

Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R,S)-ketamine and (S)-ketamine, but not (R)-ketamine.

Pharmacology, biochemistry, and behavior·2018
Same author

Is (S)-norketamine an alternative antidepressant for esketamine?

European archives of psychiatry and clinical neuroscience·2018
Same author

Author Correction: Lack of metabolism in (R)-ketamine's antidepressant actions in a chronic social defeat stress model.

Scientific reports·2018
Same author

CBL1-CIPK26-mediated phosphorylation enhances activity of the NADPH oxidase RBOHC, but is dispensable for root hair growth.

FEBS letters·2018

Related Experiment Video

Updated: Jun 29, 2025

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

14.0K

Viewpoints Sigma-1 receptor agonist fluvoxamine for multiple sclerosis.

Kenji Hashimoto1

  • 1Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba, 260-8670, Japan.

Brain, Behavior, & Immunity - Health
|March 25, 2024
PubMed
Summary

Epstein-Barr virus (EBV) is linked to multiple sclerosis (MS). The antidepressant fluvoxamine may treat MS by targeting the EBV reactivation pathway involving the XBP1-sigma-1 receptor complex.

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.0K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.6K

Related Experiment Videos

Last Updated: Jun 29, 2025

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

14.0K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.0K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.6K

Area of Science:

  • Neuroimmunology
  • Virology
  • Pharmacology

Background:

  • Epstein-Barr virus (EBV) is increasingly implicated in the pathogenesis of multiple sclerosis (MS).
  • Depressive symptoms are frequently observed preceding the clinical onset of MS.
  • The XBP1-sigma-1 receptor complex is crucial for endoplasmic reticulum function and EBV reactivation.

Purpose of the Study:

  • To explore the potential therapeutic role of fluvoxamine in multiple sclerosis.
  • To investigate the link between EBV reactivation, endoplasmic reticulum stress, and MS.
  • To propose a novel treatment strategy for MS based on targeting viral reactivation.

Main Methods:

  • Review of existing literature on EBV, MS, endoplasmic reticulum stress, and sigma-1 receptor agonists.
  • Hypothesizing a mechanism of action for fluvoxamine in the context of MS.
  • Analyzing the pharmacological properties of fluvoxamine as a sigma-1 receptor agonist.

Main Results:

  • Evidence suggests a significant association between EBV infection and MS development.
  • The XBP1-sigma-1 receptor pathway is a critical node in EBV reactivation.
  • Fluvoxamine, a selective serotonin reuptake inhibitor, also acts as a sigma-1 receptor agonist.

Conclusions:

  • Fluvoxamine's sigma-1 receptor agonism presents a potential therapeutic avenue for MS.
  • Targeting EBV reactivation via the sigma-1 receptor may mitigate MS pathogenesis.
  • This hypothesis warrants further investigation through preclinical and clinical studies.